norfloxacin has been researched along with Recrudescence in 55 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis." | 9.08 | Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. ( Aguilar, L; Caffaratti, J; Dal-Ré, R; Dalet, F; Del Río, G, 1996) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 9.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 9.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "In a single-blind, randomized study of multicentre trial design 343 hospitalized geriatric patients (median age 83 years) suffering from symptomatic urinary tract infections (UTI) were treated with either norfloxacin 200 mg twice daily or pivmecillinam 200 mg 3 times daily orally for 7 days to compare the clinical efficacy and safety of the antibiotics in the elderly." | 9.06 | Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients. ( Englund, G; Jonsson, M; Nörgård, K, 1990) |
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 9.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 9.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "To objectively evaluate the efficacy, safety and utility of lomefloxacin (NY-198), a new quinolone antibacterial agent, in the treatment of acute uncomplicated cystitis, a comparative double blind trial was performed using norfloxacin (NFLX) as the control drug." | 9.06 | [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis]. ( Amano, M; Arakawa, S; Fujita, Y; Ishigami, J; Kamidono, S; Kanemasa, Y; Kumon, H; Ohmori, H; Suzuki, K; Tanaka, H, 1989) |
| "In a multicenter, prospective treatment study, 59 patients with complicated or uncomplicated urinary tract infections (UTIs) were treated with norfloxacin (400 mg orally twice daily) and compared with 45 patients treated with trimethoprim/sulfamethoxazole." | 9.06 | Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. ( Alpert, ML; Cherubin, CE; Eng, RH; Ginsburg, BP; Goldstein, EJ; Kahn, RM; Najem, A, 1987) |
| " No significant differences in prophylactic antibiotic treatment with nitrofurantoin and norfloxacin, trimethoprim, sulfamethoxazole/trimethoprim, methamine hippurate, estriol, or cefaclor were found in clinical or microbiological cure in adult nonpregnant women with recurrent urinary tract infections (9 randomized control trials, 673 patients, relative risk ratio, 1." | 8.93 | Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. ( Gregory, WT; Guran, LA; McDonagh, MS; Price, JR, 2016) |
| "In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b." | 8.78 | Review of norfloxacin in complicated and recurrent urinary tract infections. ( Schaeffer, AJ, 1990) |
| "The effects on the long-term use of norfloxacin, a fluorinated 4-quinolone, on the intestinal flora (both aerobic and anaerobic), were evaluated in patients suffering from recurrent complicated urinary tract infections." | 7.67 | Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. ( Boerema, JB; Olthof, BJ; van Saene, HK, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 7.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| " The 200-mg dosage of norfloxacin seemed to cause fewer side effects than the 400-mg dosage." | 6.66 | Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group. ( , 1987) |
| "Norfloxacin is a lipid-soluble weak organic acid bound to plasma proteins to a low extent." | 6.66 | Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. ( Cook, T; Hoagland, VL; Sabbaj, J, 1986) |
| "The cumulative incidence of SBP recurrence was 28." | 5.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The SBP recurrence rate was 42." | 5.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 5.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| "Women with recurrent urinary tract infections received a dip slide urine culture kit and 6 tablets of norfloxacin (400 mg." | 5.09 | Efficacy and safety of self-start therapy in women with recurrent urinary tract infections. ( Schaeffer, AJ; Stuppy, BA, 1999) |
| "The efficacy and safety of rufloxacin (400 mg, single dose) were compared to those of norfloxacin (400 mg twice a day for 3 days) for the treatment of women with uncomplicated cystitis." | 5.08 | Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations. ( Aguilar, L; Caffaratti, J; Dal-Ré, R; Dalet, F; Del Río, G, 1996) |
| "Fleroxacin, 400 mg once daily, and norfloxacin, 400 mg twice daily, both administered orally, were compared for the treatment of serious urinary tract infections (UTIs)." | 5.07 | Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections. ( Childs, SJ, 1993) |
| "A total of 102 women with recurrent urinary tract infections were included in this open randomized study; 55 received 200 mg of norfloxacin daily and 47 received 50 mg of nitrofurantoin daily over 6 months." | 5.07 | Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection. ( Boger, S; Raz, R, 1991) |
| "Eighty-two evaluable patients suffering from UTI were randomly treated with parenteral Aztreonam (1 g OD in cystitis and 1 g BID in pyelonephritis) or oral Norfloxacin (400 mg BID)." | 5.06 | [Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients]. ( De Rose, AF; Germinale, F; Puppo, P, 1989) |
| "Eighty cirrhotic patients who had recovered from an episode of spontaneous bacterial peritonitis were included in a multicenter, double-blind trial aimed at comparing long-term norfloxacin administration (400 mg/day; 40 patients) vs." | 5.06 | Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial. ( Almela, M; Forné, M; Ginés, P; Llach, J; Marco, F; Miranda, ML; Planas, R; Rimola, A; Salmerón, JM; Vargas, V, 1990) |
| "Norfloxacin, a broad-spectrum antimicrobial analog of nalidixic acid, was evaluated by comparing it to trimethoprim-sulfamethoxazole in 93 office patients with recurrent urinary tract infections." | 5.06 | Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole. ( Amy, BG; Childs, SJ; Hurst, AT; Krisch, EB; McCabe, RE; Seidmon, EJ; Truant, AL, 1990) |
| "In a single-blind, randomized study of multicentre trial design 343 hospitalized geriatric patients (median age 83 years) suffering from symptomatic urinary tract infections (UTI) were treated with either norfloxacin 200 mg twice daily or pivmecillinam 200 mg 3 times daily orally for 7 days to compare the clinical efficacy and safety of the antibiotics in the elderly." | 5.06 | Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients. ( Englund, G; Jonsson, M; Nörgård, K, 1990) |
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 5.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "A randomized clinical study was conducted in order to compare the effectiveness of norfloxacin and cinoxacin in complicated urinary tract infections." | 5.06 | [Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract]. ( Cristiano, P; Della Vittoria Scarpati, M; Iovene, MR; Manguso, L; Morelli, G; Simioli, F, 1989) |
| "To objectively evaluate the efficacy, safety and utility of lomefloxacin (NY-198), a new quinolone antibacterial agent, in the treatment of acute uncomplicated cystitis, a comparative double blind trial was performed using norfloxacin (NFLX) as the control drug." | 5.06 | [A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis]. ( Amano, M; Arakawa, S; Fujita, Y; Ishigami, J; Kamidono, S; Kanemasa, Y; Kumon, H; Ohmori, H; Suzuki, K; Tanaka, H, 1989) |
| "In a multicenter, prospective treatment study, 59 patients with complicated or uncomplicated urinary tract infections (UTIs) were treated with norfloxacin (400 mg orally twice daily) and compared with 45 patients treated with trimethoprim/sulfamethoxazole." | 5.06 | Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial. ( Alpert, ML; Cherubin, CE; Eng, RH; Ginsburg, BP; Goldstein, EJ; Kahn, RM; Najem, A, 1987) |
| " No significant differences in prophylactic antibiotic treatment with nitrofurantoin and norfloxacin, trimethoprim, sulfamethoxazole/trimethoprim, methamine hippurate, estriol, or cefaclor were found in clinical or microbiological cure in adult nonpregnant women with recurrent urinary tract infections (9 randomized control trials, 673 patients, relative risk ratio, 1." | 4.93 | Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis. ( Gregory, WT; Guran, LA; McDonagh, MS; Price, JR, 2016) |
| "In seven studies of complicated and recurrent urinary tract infections, 285 patients were treated with norfloxacin 400 mg b." | 4.78 | Review of norfloxacin in complicated and recurrent urinary tract infections. ( Schaeffer, AJ, 1990) |
| "or t." | 3.76 | World-wide clinical experience with norfloxacin: efficacy and safety. ( Corrado, M; Hoagland, V; Sabbaj, J; Wang, C, 1986) |
| "The effects on the long-term use of norfloxacin, a fluorinated 4-quinolone, on the intestinal flora (both aerobic and anaerobic), were evaluated in patients suffering from recurrent complicated urinary tract infections." | 3.67 | Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections. ( Boerema, JB; Olthof, BJ; van Saene, HK, 1986) |
| "28 patients with urinary tract infections (UTI) were treated with norfloxacin 2 X 400 mg daily for 9 days." | 3.67 | [Norfloxacin in the treatment of urinary tract infections]. ( Joost, J, 1986) |
| "The effect of a single day treatment with 600 mg norfloxacin 600 mg ofloxacin or 1,920 mg trimethoprim-sulfamethoxazol was determined on 114 patients with acute cystitis." | 3.67 | [Single day treatment in acute cystitis]. ( Kawaguchi, K; Yamaguchi, K, 1988) |
| "Twenty-four patients with complicated urinary tract infections were treated with norfloxacin for three months." | 3.67 | Norfloxacin treatment in complicated urinary tract infection. ( Boerema, JB; van Saene, HK, 1986) |
| "Norfloxacin is a lipid-soluble weak organic acid bound to plasma proteins to a low extent." | 2.66 | Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men. ( Cook, T; Hoagland, VL; Sabbaj, J, 1986) |
| " The 200-mg dosage of norfloxacin seemed to cause fewer side effects than the 400-mg dosage." | 2.66 | Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group. ( , 1987) |
| "The cumulative incidence of SBP recurrence was 28." | 1.51 | Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin. ( Barcán, LA; Bermudez, C; Diaz, JM; Dirchwolf, M; Gadano, AC; Giunta, D; Gutierrez-Acevedo, MN; Marciano, S; Smud, A, 2019) |
| "The SBP recurrence rate was 42." | 1.37 | Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor. ( Chen, WT; Chiu, CT; Ho, YP; Huang, CH; Lin, CY; Lin, TN; Sheen, IS, 2011) |
| "To treat 212 cases of typhoid fever with Seven kinds of fluoroquinolones (FQNS) and to evaluate their clinical efficacy, bacterial susceptibility and adverse drug reaction (ADR)." | 1.30 | [Observation of 212 cases of typhoid fever treated with FQNS]. ( Feng, S; Jiang, S; Wang, X, 1997) |
| "The 1-year recurrence rate of SBP can be as high as 30-70%." | 1.30 | An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis. ( Ganiats, TG; McHutchison, JG; Younossi, ZM, 1997) |
| " Oral administration and twice daily dosing are significant advantages." | 1.27 | Norfloxacin in the eradication of enteric infections in AIDS patients. ( Appleman, MD; Causey, DM; Corrado, ML; Heseltine, PN; Leedom, JM, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (41.82) | 18.7374 |
| 1990's | 23 (41.82) | 18.2507 |
| 2000's | 2 (3.64) | 29.6817 |
| 2010's | 7 (12.73) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blango, MG | 1 |
| Mulvey, MA | 1 |
| Vikramjeet, S | 1 |
| Angelika, B | 1 |
| Nishtha, M | 1 |
| Marciano, S | 1 |
| Dirchwolf, M | 1 |
| Diaz, JM | 1 |
| Bermudez, C | 1 |
| Gutierrez-Acevedo, MN | 1 |
| Barcán, LA | 1 |
| Smud, A | 1 |
| Giunta, D | 1 |
| Gadano, AC | 1 |
| Dupin, N | 1 |
| Gerhardt, P | 1 |
| Price, JR | 1 |
| Guran, LA | 1 |
| Gregory, WT | 1 |
| McDonagh, MS | 1 |
| Sharma, S | 1 |
| Srinivasaraghavan, R | 1 |
| Krishnamurthy, S | 1 |
| Huang, CH | 1 |
| Lin, CY | 1 |
| Sheen, IS | 1 |
| Chen, WT | 1 |
| Lin, TN | 1 |
| Ho, YP | 1 |
| Chiu, CT | 1 |
| Norinder, BS | 1 |
| Norrby, R | 1 |
| Palmgren, AC | 1 |
| Hollenberg, S | 1 |
| Eriksson, U | 1 |
| Nord, CE | 2 |
| Schölmerich, J | 1 |
| Gerbes, AL | 1 |
| Andus, T | 1 |
| Leser, HG | 1 |
| Pfau, A | 1 |
| Sacks, TG | 1 |
| Tripathi, KD | 1 |
| Sharma, AK | 1 |
| Valecha, N | 1 |
| Kulpati, DD | 1 |
| Childs, SJ | 2 |
| Trienekens, TA | 1 |
| London, NH | 1 |
| Houben, AW | 1 |
| De Jong, RA | 1 |
| Stobberingh, EE | 1 |
| Del Río, G | 1 |
| Dalet, F | 1 |
| Aguilar, L | 1 |
| Caffaratti, J | 1 |
| Dal-Ré, R | 1 |
| Guibert, J | 1 |
| Herman, H | 1 |
| Capron, MH | 1 |
| Mavromanolakis, E | 1 |
| Maraki, S | 1 |
| Samonis, G | 1 |
| Tselentis, Y | 1 |
| Cranidis, A | 1 |
| Younossi, ZM | 1 |
| McHutchison, JG | 1 |
| Ganiats, TG | 1 |
| Levadoux, M | 1 |
| Carli, P | 1 |
| Gadea, JF | 1 |
| De Mauleon De Bruyere, P | 1 |
| Perre, C | 1 |
| Jiang, S | 1 |
| Wang, X | 1 |
| Feng, S | 1 |
| Caron, F | 1 |
| Schaeffer, AJ | 3 |
| Stuppy, BA | 1 |
| Cronberg, S | 1 |
| Banke, S | 1 |
| Bergman, B | 1 |
| Boman, H | 1 |
| Eilard, T | 1 |
| Elbel, E | 1 |
| Hugo-Persson, M | 1 |
| Johansson, E | 1 |
| Kuylenstierna, N | 1 |
| Lanbeck, P | 1 |
| Lindblom, A | 1 |
| Paulsen, O | 1 |
| Schönbeck, C | 1 |
| Walder, M | 1 |
| Wieslander, P | 1 |
| Saginur, R | 1 |
| Nicolle, LE | 2 |
| Toba, K | 1 |
| Harada, N | 1 |
| Inoue, G | 1 |
| Orimo, H | 1 |
| Shimada, K | 1 |
| Saga, M | 1 |
| Sawada, T | 1 |
| Hoshino, T | 1 |
| Ohata, N | 1 |
| Brumfitt, W | 1 |
| Hamilton-Miller, JM | 1 |
| Smith, GW | 1 |
| al-Wali, W | 1 |
| Raz, R | 1 |
| Boger, S | 1 |
| Goldstein, EJ | 2 |
| Jonsson, M | 1 |
| Englund, G | 2 |
| Nörgård, K | 1 |
| Sandberg, T | 1 |
| Lincoln, K | 1 |
| Nilsson, LG | 1 |
| Ginés, P | 1 |
| Rimola, A | 1 |
| Planas, R | 1 |
| Vargas, V | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Forné, M | 1 |
| Miranda, ML | 1 |
| Llach, J | 1 |
| Salmerón, JM | 1 |
| Seidmon, EJ | 1 |
| Krisch, EB | 1 |
| Truant, AL | 1 |
| Amy, BG | 1 |
| Hurst, AT | 1 |
| McCabe, RE | 1 |
| Puppo, P | 1 |
| Germinale, F | 1 |
| De Rose, AF | 1 |
| Edlund, C | 1 |
| Cristiano, P | 1 |
| Morelli, G | 1 |
| Simioli, F | 1 |
| Iovene, MR | 1 |
| Della Vittoria Scarpati, M | 1 |
| Manguso, L | 1 |
| Ohmori, H | 1 |
| Kumon, H | 1 |
| Suzuki, K | 1 |
| Kamidono, S | 1 |
| Arakawa, S | 1 |
| Ishigami, J | 1 |
| Tanaka, H | 1 |
| Amano, M | 1 |
| Fujita, Y | 1 |
| Kanemasa, Y | 1 |
| Harding, GK | 1 |
| Thompson, M | 1 |
| Kennedy, J | 1 |
| Urias, B | 1 |
| Ronald, AR | 1 |
| Ewer, TC | 1 |
| Bailey, RR | 1 |
| Gilchrist, NL | 1 |
| Aitken, JM | 1 |
| Sainsbury, R | 1 |
| Lachaux, A | 1 |
| Descos, B | 1 |
| Loras-Duclaux, I | 1 |
| Souillet, G | 1 |
| Floret, D | 1 |
| Brunet, J | 1 |
| Freney, J | 1 |
| Hermier, M | 1 |
| Yamaguchi, K | 1 |
| Kawaguchi, K | 1 |
| Falck, L | 1 |
| Bucht, H | 1 |
| Stegmayr, B | 1 |
| Svärd, R | 1 |
| Boerema, JB | 2 |
| Olthof, BJ | 1 |
| van Saene, HK | 2 |
| Bischoff, W | 1 |
| Heseltine, PN | 1 |
| Causey, DM | 1 |
| Appleman, MD | 1 |
| Corrado, ML | 1 |
| Leedom, JM | 1 |
| Alpert, ML | 1 |
| Najem, A | 1 |
| Eng, RH | 1 |
| Ginsburg, BP | 1 |
| Kahn, RM | 1 |
| Cherubin, CE | 1 |
| Rugendorff, E | 1 |
| Haralambie, E | 1 |
| Sabbaj, J | 2 |
| Hoagland, VL | 1 |
| Cook, T | 1 |
| Westenfelder, M | 1 |
| Vahlensieck, W | 1 |
| Reinhartz, U | 1 |
| Joost, J | 1 |
| Wang, C | 1 |
| Corrado, M | 1 |
| Hoagland, V | 1 |
| Karachalios, GN | 1 |
| Georgiopoulos, AN | 1 |
| Ganguli, LA | 1 |
| Keaney, MG | 1 |
| Gould, LJ | 1 |
7 reviews available for norfloxacin and Recrudescence
| Article | Year |
|---|---|
Nitrofurantoin vs other prophylactic agents in reducing recurrent urinary tract infections in adult women: a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Cefaclor; Estriol; Female; Humans; Nit | 2016 |
[Spontaneous bacterial peritonitis in liver cirrhosis with ascites].
Topics: Anti-Bacterial Agents; Ascites; Bacteria; Bacterial Infections; Blood; Endoscopy; Humans; Leukocyte | 1995 |
[Current role of aminoglycosides in the treatment of acute pyelonephritis].
Topics: Acute Disease; Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefadroxil | 1998 |
Prevention of bacterial resistance in urinary tract infections.
Topics: Drug Resistance, Microbial; Humans; Norfloxacin; Recurrence; Urinary Tract Infections | 1991 |
Review of norfloxacin in complicated and recurrent urinary tract infections.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Norfloxacin; Recurrence; Urinary Tract I | 1990 |
Clinical impact of newer quinolones: influence on normal microflora.
Topics: Bacterial Infections; Ciprofloxacin; Humans; Immune Tolerance; Intestinal Mucosa; Norfloxacin; Oroph | 1989 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
29 trials available for norfloxacin and Recrudescence
| Article | Year |
|---|---|
Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection.
Topics: Adolescent; Adult; Amdinocillin Pivoxil; Bacteria; Double-Blind Method; Female; Humans; Middle Aged; | 2006 |
Effective postcoital quinolone prophylaxis of recurrent urinary tract infections in women.
Topics: Adult; Ciprofloxacin; Coitus; Female; Humans; Norfloxacin; Ofloxacin; Prospective Studies; Recurrenc | 1994 |
Fleroxacin versus norfloxacin for oral treatment of serious urinary tract infections.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Flero | 1993 |
Treating acute urinary tract infections. An RCT of 3-day versus 7-day norfloxacin.
Topics: Absenteeism; Acute Disease; Adolescent; Adult; Aged; Double-Blind Method; Escherichia coli Infection | 1993 |
Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.
Topics: Adult; Anti-Infective Agents; Cystitis; Escherichia coli Infections; Female; Fluoroquinolones; Human | 1996 |
[Treatment of uncomplicated recurrent cystitis in women: lomefloxacin versus norfloxacin].
Topics: Adult; Anti-Infective Agents; Cystitis; Drug Administration Schedule; Female; Fluoroquinolones; Huma | 1997 |
Effect of norfloxacin, trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent urinary tract infections.
Topics: Adult; Anti-Infective Agents, Urinary; Enterobacteriaceae; Enterococcus; Feces; Female; Humans; Midd | 1997 |
Efficacy and safety of self-start therapy in women with recurrent urinary tract infections.
Topics: Adult; Anti-Infective Agents; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Norfloxacin; | 1999 |
Fewer bacterial relapses after oral treatment with norfloxacin than with ceftibuten in acute pyelonephritis initially treated with intravenous cefuroxime.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Ceftibut | 2001 |
Single-dose compared with 3-day norfloxacin treatment of uncomplicated urinary tract infection in women. Canadian Infectious Diseases Society Clinical Trials Study Group.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Double-Blind Method; Drug Administration | 1992 |
[Long-term single dose chemoprophylaxis of recurrent urinary tract infection in elderly female subjects].
Topics: Aged; Aged, 80 and over; Female; Humans; Norfloxacin; Recurrence; Time Factors; Urinary Tract Infect | 1991 |
Comparative trial of norfloxacin and macrocrystalline nitrofurantoin (Macrodantin) in the prophylaxis of recurrent urinary tract infection in women.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Nitrofurantoin; Norfloxacin | 1991 |
Long-term prophylaxis with norfloxacin versus nitrofurantoin in women with recurrent urinary tract infection.
Topics: Female; Humans; Middle Aged; Nitrofurantoin; Norfloxacin; Recurrence; Urinary Tract Infections | 1991 |
Norfloxacin vs. pivmecillinam in the treatment of uncomplicated lower urinary tract infections in hospitalized elderly patients.
Topics: Aged; Aged, 80 and over; Amdinocillin; Amdinocillin Pivoxil; Clinical Trials as Topic; Female; Human | 1990 |
Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Bacteriuria; Cefadroxil; Chi-Square Distr | 1990 |
Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial.
Topics: Bacterial Infections; Double-Blind Method; Drug Administration Schedule; Feces; Female; Humans; Live | 1990 |
Treatment of recurrent urinary tract infection with norfloxacin versus trimethoprim-sulfamethoxazole.
Topics: Adult; Aged; Aged, 80 and over; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norf | 1990 |
[Aztreonam vs norfloxacin: a comparative study of the treatment of urinary tract infections in ambulatory and hospitalized patients].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Aztreonam; Clinical Trials as Topic; Cystitis; F | 1989 |
[Comparative evaluation of norfloxacin and cinoxacin in the therapy of complicated infections of the urinary tract].
Topics: Bacteria; Bacteriuria; Cinoxacin; Clinical Trials as Topic; Drug Tolerance; Female; Humans; Male; Mi | 1989 |
[A comparative study on lomefloxacin and norfloxacin in the treatment of acute uncomplicated cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; Bacteria; Child; Clinical Trials as T | 1989 |
Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Microbial Sensitivity Tests; N | 1989 |
Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections. The Urinary Tract Infection Study Group.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Double-Blind Method; Drug Combinations; Fe | 1987 |
Comparative study of norfloxacin and trimethoprim for the treatment of elderly patients with urinary tract infection.
Topics: Aged; Aged, 80 and over; Bacterial Infections; Bacteriuria; Clinical Trials as Topic; Enterobacteria | 1988 |
Multiclinic study of norfloxacin for treatment of urinary tract infections.
Topics: Clinical Trials as Topic; Drug Resistance, Microbial; Female; Gram-Negative Bacteria; Gram-Positive | 1987 |
Norfloxacin in the treatment of complicated and uncomplicated urinary tract infections. A comparative multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Drug Combinations; Female; Humans; Male; M | 1987 |
Low-dose norfloxacin versus placebo for long-term prophylaxis of recurrent uncomplicated urinary tract infection.
Topics: Adult; Aged; Bacteria; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Microbial Sens | 1987 |
Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men.
Topics: Anti-Infective Agents, Urinary; Bacteria; Drug Combinations; Humans; Male; Microbial Sensitivity Tes | 1986 |
World-wide clinical experience with norfloxacin: efficacy and safety.
Topics: Acute Disease; Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Diarrhea; Gastroente | 1986 |
Norfloxacin versus nalidixic acid in the treatment of urinary tract infections.
Topics: Adult; Aged; Bacterial Infections; Bacteriuria; Female; Humans; Male; Middle Aged; Nalidixic Acid; N | 1987 |
20 other studies available for norfloxacin and Recrudescence
| Article | Year |
|---|---|
Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cell Membrane Permeability; Cells, Cultured; Drug Resistan | 2010 |
Norfloxacin Induced Recurrent Fixed Drug Eruption in a self Treated Adult Female Patient - A Case Report.
Topics: Adult; Anti-Bacterial Agents; Dermabrasion; Drug Eruptions; Female; Humans; Norfloxacin; Recurrence; | 2019 |
Spontaneous bacterial peritonitis recurrence in patients with cirrhosis receiving secondary prophylaxis with norfloxacin.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bacterial Infections; Female; Humans; Li | 2019 |
[Diagnosis of sexually transmitted diseases: case studies].
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Carcinoma, Squamous Cell; Diagn | 2013 |
Central Nervous System Symptoms Due to Transient Methemoglobinemia in a Child With G6PD Deficiency.
Topics: Acute Disease; Child, Preschool; Consanguinity; Cyanosis; Glucosephosphate Dehydrogenase Deficiency; | 2017 |
Recurrence of spontaneous bacterial peritonitis in cirrhotic patients non-prophylactically treated with norfloxacin: serum albumin as an easy but reliable predictive factor.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Female; Humans; Liver Cirrhosis; Logistic Models; Male; | 2011 |
Curative efficacy of norfloxacin in falciparum malaria.
Topics: Adolescent; Adult; Chloroquine; Drug Administration Schedule; Female; Humans; Malaria, Falciparum; M | 1993 |
An economic analysis of norfloxacin prophylaxis against spontaneous bacterial peritonitis.
Topics: Anti-Infective Agents; Bacterial Infections; Cost Savings; Health Care Costs; Humans; Life Expectanc | 1997 |
[Repeated rupture of the extensor tendons of the hand due to fluoroquinolones. Apropos of a case].
Topics: Acute Disease; Aged; Anti-Infective Agents; Blood Vessels; Chronic Disease; Female; Hand; Hemosidero | 1997 |
[Observation of 212 cases of typhoid fever treated with FQNS].
Topics: Adult; Anti-Infective Agents; Child; Ciprofloxacin; Enoxacin; Humans; Norfloxacin; Recurrence; Typho | 1997 |
[Recurrent infections caused by Salmonella typhimurium].
Topics: Anti-Bacterial Agents; Child, Preschool; Female; Humans; Immunologic Deficiency Syndromes; Neutrophi | 1988 |
[Single day treatment in acute cystitis].
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Urinary; Cystitis; | 1988 |
Suppressive therapy with norfloxacin in patients with recurrent and/or complicated urinary tract infection.
Topics: Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin; Recurrence; Time Factor | 1988 |
Effects of norfloxacin on the faecal flora in patients with complicated urinary tract infections.
Topics: Bacteria, Aerobic; Bacteria, Anaerobic; Candida; Enterobacteriaceae; Enterococcus faecalis; Feces; H | 1986 |
[Norfloxacin treatment of acute cystitis in the female and bacterial prostatitis].
Topics: Adult; Anti-Infective Agents, Urinary; Bacterial Infections; Cystitis; Female; Humans; Male; Microbi | 1985 |
Norfloxacin in the eradication of enteric infections in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Humans; Intestinal Diseases; Male; Norfloxacin; Recurrenc | 1988 |
Norfloxacin treatment in complicated urinary tract infection.
Topics: Adolescent; Adult; Aged; Bacteriuria; Child; Enterobacteriaceae Infections; Female; Humans; Male; Mi | 1986 |
Patient compliance and efficacy of low-dose, long-term prophylaxis in patients with recurrent urinary tract infection.
Topics: Adult; Anti-Infective Agents; Child; Follow-Up Studies; Humans; Norfloxacin; Patient Compliance; Pyr | 1987 |
[Norfloxacin in the treatment of urinary tract infections].
Topics: Adolescent; Adult; Aged; Escherichia coli Infections; Female; Humans; Male; Middle Aged; Norfloxacin | 1986 |
Norfloxacin: a three-day course for the treatment of urinary tract infection.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Nausea; Nor | 1985 |